Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...

After years of unexplained pain in her joints, nerves, and stomach, this writer finally found some relief—and a new community ...

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis (MG). | Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis.

Key Points GAAP EPS loss was $(0.88) for Q2 2025 GAAP revenue was $0.2 million for Q2 2025 Research and development expenses increased by 45.3%, while general and administrative expenses rose by 48.3% ...

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, immune-mediated neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms ...